General Information of Drug Combination (ID: DCE0YDY)

Drug Combination Name
DFN-15 Vinflunine
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs DFN-15   DM3BF9B Vinflunine   DMTJAEP
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: LOX IMVI
Zero Interaction Potency (ZIP) Score: 6.89
Bliss Independence Score: 12.28
Loewe Additivity Score: 3.08
LHighest Single Agent (HSA) Score: 2.14

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCUUQPO MOLT-4 Investigative [4]
Childhood T acute lymphoblastic leukemia DCG5YAD CCRF-CEM Investigative [4]
Chronic myelogenous leukemia DC98440 K-562 Investigative [4]
Clear cell renal cell carcinoma DC1ZLKQ 786-0 Investigative [4]
Glioblastoma DC7NT7W SNB-75 Investigative [4]
Plasma cell myeloma DCZ7IPY RPMI-8226 Investigative [4]
Invasive ductal carcinoma DCYHMLY HS 578T Investigative [5]
Adenocarcinoma DCMQNBG OVCAR3 Investigative [1]
Adenocarcinoma DCGSSDF NCIH23 Investigative [1]
Cutaneous melanoma DC7T3FR SK-MEL-5 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.